Clinical Trials Browser

Withdrawn × Nivolumab × Head & Neck × Clear all

NCT05743270 2025-03-11

Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Phase 2 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT05472506 2024-03-15

Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04891718 2022-07-08

CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

Phase EARLY_PHASE1 Withdrawn

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT03390738 2021-05-03

Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy

Phase 2 Withdrawn

Nasopharyngeal Carcinoma

NCT03342352 2019-12-20

Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)

Phase 3 Withdrawn

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03575234 2019-08-28

Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck

NCT03386838 2019-04-18

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Phase 3 Withdrawn

Head and Neck Neoplasms